I am new here but I agree. Having sold many Pharma

I am new here but I agree. Having sold many Pharma drugs "pull through"
is very important. In addition, communicating the UNIQUE features of the drug and the UNIQUE benefits in a simple message that everyone can understand that clearly distinguishes Leronlamab from all other CCR5. The interview with Nader and Dr. B is a perfect example.

Will the Mild to moderate data come out first? I worry about that because the current protocol for those patients is to 1) call primary care Dr. 2) Go to lab to be tested if meet certain criteria. 3) go home and wait it out. I don't see an opportunity for the Dr. to intervene unless patient progresses to critical and is in the hospital at which point the drug would be available- if the procurement department orders it, which is a function of critical care doc awareness and " push through".

We need to 1) get as much general public attention ( in my experience Dr.s hate direct to consume advertising so PR and media is a must 2) Government attention. 3) Primary Care Doc attention. Also, insurance companies need all the cost saving data to consider coverage. If this was a first in class drug it would automatically be covered. Not sure if the unique MOA counts. These are just some thoughts from a very minor stock holder who believes Leronlamab is a God send.